MX2021014541A - Composicion farmacéutica para diabetes mellitus. - Google Patents
Composicion farmacéutica para diabetes mellitus.Info
- Publication number
- MX2021014541A MX2021014541A MX2021014541A MX2021014541A MX2021014541A MX 2021014541 A MX2021014541 A MX 2021014541A MX 2021014541 A MX2021014541 A MX 2021014541A MX 2021014541 A MX2021014541 A MX 2021014541A MX 2021014541 A MX2021014541 A MX 2021014541A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- diabetes mellitus
- relates
- present
- composition
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 abstract 1
- 229960001254 vildagliptin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica de inhibidores de dipeptidil peptidasa IV (DPP-IV) para uso en el tratamiento de diabetes mellitus (DM). En particular, la presente invención se refiere a una forma farmacéutica de liberación prolongada o modificada que comprende una composición de vildagliptina o una sal farmacéuticamente aceptable de la misma con los parámetros físicos y químicos deseados para un mejor cumplimiento terapéutico del paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201921021312 | 2019-05-29 | ||
PCT/IN2020/050480 WO2020240594A1 (en) | 2019-05-29 | 2020-05-29 | A pharmaceutical composition for diabetes mellitus |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021014541A true MX2021014541A (es) | 2022-02-11 |
Family
ID=71738258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021014541A MX2021014541A (es) | 2019-05-29 | 2020-05-29 | Composicion farmacéutica para diabetes mellitus. |
Country Status (7)
Country | Link |
---|---|
BR (1) | BR112021024099A2 (es) |
CL (1) | CL2021003152A1 (es) |
CO (1) | CO2021018031A2 (es) |
CR (1) | CR20220001A (es) |
MX (1) | MX2021014541A (es) |
PE (1) | PE20220644A1 (es) |
WO (1) | WO2020240594A1 (es) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY152185A (en) * | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
WO2016016772A1 (en) * | 2014-07-26 | 2016-02-04 | Wockhardt Limited | A novel modified release pharmaceutical composition of dpp-iv inhibitors or pharmaceutically acceptable salt thereof |
-
2020
- 2020-05-29 BR BR112021024099A patent/BR112021024099A2/pt unknown
- 2020-05-29 WO PCT/IN2020/050480 patent/WO2020240594A1/en active Application Filing
- 2020-05-29 CR CR20220001A patent/CR20220001A/es unknown
- 2020-05-29 PE PE2021001978A patent/PE20220644A1/es unknown
- 2020-05-29 MX MX2021014541A patent/MX2021014541A/es unknown
-
2021
- 2021-11-26 CL CL2021003152A patent/CL2021003152A1/es unknown
- 2021-12-29 CO CONC2021/0018031A patent/CO2021018031A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021024099A2 (pt) | 2022-01-11 |
CO2021018031A2 (es) | 2022-04-19 |
CR20220001A (es) | 2022-03-21 |
PE20220644A1 (es) | 2022-04-28 |
WO2020240594A1 (en) | 2020-12-03 |
CL2021003152A1 (es) | 2022-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ603319A (en) | Diabetes therapy | |
MX351232B (es) | Inhibidor de dpp-iv combinado con otro agente antidiabetico, tabletas que comprenden tales formulaciones, su uso y procedimiento para su preparacion. | |
PL1928499T3 (pl) | Zastosowanie inhibitora DPP-IV do ograniczania epizodów hipoglikemii | |
MX2010009731A (es) | Composiciones farmaceuticas de una combinacion de metformina y un inhibidor de dipeptidil peptidasa-iv. | |
MX2020009811A (es) | Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico. | |
MX2011007397A (es) | Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos. | |
MX2013008484A (es) | Prevencion de hidroglucemia en pacientes con diabetes mellitus tipo 2. | |
MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
MX2019012884A (es) | Terapia de combinacion. | |
SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
PH12020551939A1 (en) | Pharmaceutical composition comprising sglt-2 inhibitor and dpp-iv inhibitor | |
MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
MX2020010322A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak). | |
RS52629B (en) | LIXISENATIDE AS ADDITIONAL THERAPY INSULIN GLARGINE AND METFORMIN FOR TYPE 2 DIABETES TREATMENT | |
MX339614B (es) | Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2. | |
MX2021002321A (es) | Nuevos metodos. | |
UA88481C2 (ru) | Донепезила фумарат, пригодный для получения фармацевтических композиций | |
MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
PH12017501662A1 (en) | Treatment type 2 diabetes mellitus patients | |
WO2018005794A3 (en) | Novel non-systemic tgr5 agonists | |
MX2022001647A (es) | Terapia de combinacion con vildagliptina y metformina. | |
PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
MX2019014687A (es) | Formulaciones farmaceuticas orales de remogliflozina. | |
MX2021014541A (es) | Composicion farmacéutica para diabetes mellitus. |